NCT05186623View on ClinicalTrials.gov

Prediction Model for Response to Biologics and Small Molecular Agent for UC

RecruitingOBSERVATIONAL
Enrollment

300

Participants

Timeline

Start Date

February 5, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
Ulcerative Colitis
Interventions
DRUG

Vedolizumab, Ustekinumab, or Tofacitinib

Drug administration and prospective follow-up for evaluating response

Trial Locations (1)

05505

RECRUITING

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER